Mylan offers discounts on EpiPen amid criticism
It is latest firm to be caught up in outrage at apparently egregious drug price increases
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
MYLAN NV said on Thursday it would reduce the out-of-pocket costs of its emergency EpiPen allergy injection for some patients amid a wave of criticism from lawmakers and the public over the product's rapidly escalating price.
The list price of the drug will remain the same, but the company said it would increase the maximum copay assistance programme to US$300 from US$100 for patients who pay for the 2-pak in cash or who are covered by a commercial health insurer.
Share with us your feedback on BT's products and services
TRENDING NOW
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Higher costs, lower returns: Why are Singaporeans still betting on real estate?
South-east Asian markets account for 8.8% of global capital inflows from 2021 to 2024: report
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
